Press Release
Communiqué de presse
–
June 15, 2022
15 June, 2022
Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
LONDON, Ontario – June 15, 2022 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-
stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis,
President & CEO of Sernova Corp., will be participating in the Truist Securities Cell Therapy Symposium,
Symposia-cel being held in person at the Lotte New York Palace on Tuesday, June 28, 2022. Company
management will also be participating in 1×1 meetings during the event.
Truist Securities Cell Therapy Symposium, Symposia-cel – June 28, 2022
Panel Title: Cell Therapy for Non-Oncology Indications
Date: Tuesday, June 28, 2022
Time: 2:00-3:00 PM ET
Presenter:
Dr. Philip Toleikis, President & CEO, Sernova Corp
Location: Lotte New York Palace*
* Further details available on the Truist event website
If you are interested in arranging a 1×1 meeting request, please contact your Truist representative.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic
technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders
including hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent
diabetes with its lead asset, the Cell-Pouch System, a novel implantable and scalable medical device with
immune protected therapeutic cells. The Cell Pouch on implantation forms a natural vascularized tissue
environment in the body for long-term survival and function of therapeutic cells that release necessary proteins
or factors missing from the body to treat chronic diseases. Sernova’s Cell Pouch System has already shown it
can potentially provide a ‘functional cure’ to people with type 1 diabetes in an ongoing Phase I/II clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to cloak the therapeutic cells from the immune system attack with the goal to eliminate the
need for chronic immunosuppressives. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell
replacement therapy. This partnership provides Sernova an unlimited supply of insulin-producing cells to treat
millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the
clinic in two additional programs that utilize its Cell Pouch System – an implantable cell therapy for benign
thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor 8 gene therapy for
hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
Media:
Elizabeth Miller, M.D.
LifeSci Communications
emiller@lifescicomms.com